ID   ERBB3_HUMAN             Reviewed;        1342 AA.
AC   P21860; A8K6L6; B4DIK7; B4DV32; E9PDT8; Q9BUD7;
DT   01-MAY-1991, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1991, sequence version 1.
DT   12-OCT-2022, entry version 239.
DE   RecName: Full=Receptor tyrosine-protein kinase erbB-3;
DE            EC=2.7.10.1;
DE   AltName: Full=Proto-oncogene-like protein c-ErbB-3;
DE   AltName: Full=Tyrosine kinase-type cell surface receptor HER3;
DE   Flags: Precursor;
GN   Name=ERBB3; Synonyms=HER3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=2687875; DOI=10.1073/pnas.86.23.9193;
RA   Kraus M.H., Issing W., Miki T., Popescu N.C., Aaronson S.A.;
RT   "Isolation and characterization of ERBB3, a third member of the
RT   ERBB/epidermal growth factor receptor family: evidence for overexpression
RT   in a subset of human mammary tumors.";
RL   Proc. Natl. Acad. Sci. U.S.A. 86:9193-9197(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=2164210; DOI=10.1073/pnas.87.13.4905;
RA   Plowman G.D., Whitney G.S., Neubauer M.G., Green J.M., McDonald V.L.,
RA   Todaro G.J., Shoyab M.;
RT   "Molecular cloning and expression of an additional epidermal growth factor
RT   receptor-related gene.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:4905-4909(1990).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=Placenta;
RX   PubMed=7685162; DOI=10.1006/bbrc.1993.1542;
RA   Katoh M., Yazaki Y., Sugimura T., Terada M.;
RT   "c-erbB3 gene encodes secreted as well as transmembrane receptor tyrosine
RT   kinase.";
RL   Biochem. Biophys. Res. Commun. 192:1189-1197(1993).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 4 AND 5).
RC   TISSUE=Hippocampus, Placenta, and Small intestine;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16541075; DOI=10.1038/nature04569;
RA   Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y.,
RA   Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C.,
RA   Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M., Kovar-Smith C.,
RA   Lewis L.R., Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R.,
RA   Montgomery K.T., Morgan M.B., Nazareth L.V., Scott G., Sodergren E.,
RA   Song X.-Z., Steffen D., Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y.,
RA   Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G.,
RA   Chen Z., Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H.,
RA   Draper H., Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S.,
RA   Kelly S.H., Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M.,
RA   Nguyen B.-V., Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H.,
RA   Santibanez J., Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q.,
RA   Williams G.A., Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V.,
RA   Bailey M., Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E.,
RA   Burkett C.E., Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K.,
RA   Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D.,
RA   Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M., Dathorne S.R.,
RA   David R., Davis C.M., Davy-Carroll L., Deshazo D.R., Donlin J.E.,
RA   D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J., Escotto M., Flagg N.,
RA   Forbes L.D., Gabisi A.M., Garza M., Hamilton C., Henderson N.,
RA   Hernandez O., Hines S., Hogues M.E., Huang M., Idlebird D.G., Johnson R.,
RA   Jolivet A., Jones S., Kagan R., King L.M., Leal B., Lebow H., Lee S.,
RA   LeVan J.M., Lewis L.C., London P., Lorensuhewa L.M., Loulseged H.,
RA   Lovett D.A., Lucier A., Lucier R.L., Ma J., Madu R.C., Mapua P.,
RA   Martindale A.D., Martinez E., Massey E., Mawhiney S., Meador M.G.,
RA   Mendez S., Mercado C., Mercado I.C., Merritt C.E., Miner Z.L., Minja E.,
RA   Mitchell T., Mohabbat F., Mohabbat K., Montgomery B., Moore N., Morris S.,
RA   Munidasa M., Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O.,
RA   Nwokenkwo S., Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J.,
RA   Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A.,
RA   Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M.,
RA   Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I.,
RA   Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A.,
RA   Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D., Trejos Z.Y.,
RA   Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I., Vera V.A.,
RA   Villasana D.M., Wang L., Ward-Moore S., Warren J.T., Wei X., White F.,
RA   Williamson A.L., Wleczyk R., Wooden H.S., Wooden S.H., Yen J., Yoon L.,
RA   Yoon V., Zorrilla S.E., Nelson D., Kucherlapati R., Weinstock G.,
RA   Gibbs R.A.;
RT   "The finished DNA sequence of human chromosome 12.";
RL   Nature 440:346-351(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3).
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   INTERACTION WITH GRB7.
RX   PubMed=9516479; DOI=10.1074/jbc.273.13.7717;
RA   Fiddes R.J., Campbell D.H., Janes P.W., Sivertsen S.P., Sasaki H.,
RA   Wallasch C., Daly R.J.;
RT   "Analysis of Grb7 recruitment by heregulin-activated erbB receptors reveals
RT   a novel target selectivity for erbB3.";
RL   J. Biol. Chem. 273:7717-7724(1998).
RN   [9]
RP   INTERACTION WITH PA2G4.
RX   PubMed=11325528; DOI=10.1016/s0303-7207(01)00387-2;
RA   Lessor T.J., Hamburger A.W.;
RT   "Regulation of the ErbB3 binding protein Ebp1 by protein kinase C.";
RL   Mol. Cell. Endocrinol. 175:185-191(2001).
RN   [10]
RP   INTERACTION WITH MUC1.
RX   PubMed=12939402;
RA   Li Y., Yu W.-H., Ren J., Chen W., Huang L., Kharbanda S., Loda M., Kufe D.;
RT   "Heregulin targets gamma-catenin to the nucleolus by a mechanism dependent
RT   on the DF3/MUC1 oncoprotein.";
RL   Mol. Cancer Res. 1:765-775(2003).
RN   [11]
RP   INTERACTION WITH CSPG5, AND FUNCTION.
RX   PubMed=15358134; DOI=10.1016/j.bbrc.2004.07.066;
RA   Kinugasa Y., Ishiguro H., Tokita Y., Oohira A., Ohmoto H., Higashiyama S.;
RT   "Neuroglycan C, a novel member of the neuregulin family.";
RL   Biochem. Biophys. Res. Commun. 321:1045-1049(2004).
RN   [12]
RP   INTERACTION WITH PA2G4.
RX   PubMed=16832058; DOI=10.1073/pnas.0602923103;
RA   Liu Z., Ahn J.Y., Liu X., Ye K.;
RT   "Ebp1 isoforms distinctively regulate cell survival and differentiation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:10917-10922(2006).
RN   [13]
RP   INVOLVEMENT IN LCCS2.
RX   PubMed=17701904; DOI=10.1086/520770;
RA   Narkis G., Ofir R., Manor E., Landau D., Elbedour K., Birk O.S.;
RT   "Lethal congenital contractural syndrome type 2 (LCCS2) is caused by a
RT   mutation in ERBB3 (Her3), a modulator of the phosphatidylinositol-3-
RT   kinase/Akt pathway.";
RL   Am. J. Hum. Genet. 81:589-595(2007).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [15]
RP   FUNCTION, BINDING TO NRG1, IDENTIFICATION IN A COMPLEX WITH NRG1 AND
RP   INTEGRINS, AND PHOSPHORYLATION.
RX   PubMed=20682778; DOI=10.1074/jbc.m110.113878;
RA   Ieguchi K., Fujita M., Ma Z., Davari P., Taniguchi Y., Sekiguchi K.,
RA   Wang B., Takada Y.K., Takada Y.;
RT   "Direct binding of the EGF-like domain of neuregulin-1 to integrins
RT   ({alpha}v{beta}3 and {alpha}6{beta}4) is involved in neuregulin-1/ErbB
RT   signaling.";
RL   J. Biol. Chem. 285:31388-31398(2010).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-686, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-686 AND SER-982, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 20-640, DISULFIDE BONDS, AND
RP   GLYCOSYLATION AT ASN-250; ASN-353; ASN-408; ASN-414; ASN-437; ASN-469;
RP   ASN-522 AND ASN-566.
RX   PubMed=12154198; DOI=10.1126/science.1074611;
RA   Cho H.S., Leahy D.J.;
RT   "Structure of the extracellular region of HER3 reveals an interdomain
RT   tether.";
RL   Science 297:1330-1333(2002).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 698-1019 IN COMPLEX WITH AMP-PNP,
RP   AND SUBUNIT.
RX   PubMed=20007378; DOI=10.1073/pnas.0912101106;
RA   Jura N., Shan Y., Cao X., Shaw D.E., Kuriyan J.;
RT   "Structural analysis of the catalytically inactive kinase domain of the
RT   human EGF receptor 3.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:21608-21613(2009).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 684-1020 IN COMPLEX WITH AMP-PNP,
RP   CATALYTIC ACTIVITY, MUTAGENESIS OF LYS-742 AND TYR-868,
RP   AUTOPHOSPHORYLATION, AND SUBUNIT.
RX   PubMed=20351256; DOI=10.1073/pnas.1002753107;
RA   Shi F., Telesco S.E., Liu Y., Radhakrishnan R., Lemmon M.A.;
RT   "ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze
RT   autophosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:7692-7697(2010).
RN   [21]
RP   STRUCTURE BY NMR OF 640-670, AND SUBUNIT.
RX   PubMed=21575594; DOI=10.1016/j.bbamem.2011.04.017;
RA   Mineev K.S., Khabibullina N.F., Lyukmanova E.N., Dolgikh D.A.,
RA   Kirpichnikov M.P., Arseniev A.S.;
RT   "Spatial structure and dimer-monomer equilibrium of the ErbB3 transmembrane
RT   domain in DPC micelles.";
RL   Biochim. Biophys. Acta 1808:2081-2088(2011).
RN   [22]
RP   VARIANTS [LARGE SCALE ANALYSIS] TYR-20; LEU-30; MET-104; ILE-204; TRP-683;
RP   LEU-717; THR-744; ARG-998; CYS-1119; HIS-1127; ILE-1177 AND LYS-1254.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [23]
RP   VARIANT FERLK THR-1337, CHARACTERIZATION OF VARIANT FERLK THR-1337,
RP   INVOLVEMENT IN FERLK, AND FUNCTION.
RX   PubMed=27416908; DOI=10.1038/leu.2016.173;
RA   Braunstein E.M., Li R., Sobreira N., Marosy B., Hetrick K., Doheny K.,
RA   Gocke C.D., Valle D., Brodsky R.A., Cheng L.;
RT   "A germline ERBB3 variant is a candidate for predisposition to erythroid
RT   MDS/erythroleukemia.";
RL   Leukemia 30:2242-2245(2016).
RN   [24]
RP   INVOLVEMENT IN VSCN1, VARIANTS VSCN1 PRO-787; SER-873; MET-899 AND ARG-932,
RP   CHARACTERIZATION OF VARIANTS VSCN1 PRO-787; SER-873; MET-899 AND ARG-932,
RP   SUBCELLULAR LOCATION, AND PHOSPHORYLATION.
RX   PubMed=33497358; DOI=10.1172/jci145837;
RA   Le T.L., Galmiche L., Levy J., Suwannarat P., Hellebrekers D.M.,
RA   Morarach K., Boismoreau F., Theunissen T.E., Lefebvre M., Pelet A.,
RA   Martinovic J., Gelot A., Guimiot F., Calleroz A., Gitiaux C., Hully M.,
RA   Goulet O., Chardot C., Drunat S., Capri Y., Bole-Feysot C., Nitschke P.,
RA   Whalen S., Mouthon L., Babcock H.E., Hofstra R., de Coo I.F., Tabet A.C.,
RA   Molina T.J., Keren B., Brooks A., Smeets H.J., Marklund U., Gordon C.T.,
RA   Lyonnet S., Amiel J., Bondurand N.;
RT   "Dysregulation of the NRG1/ERBB pathway causes a developmental disorder
RT   with gastrointestinal dysmotility in humans.";
RL   J. Clin. Invest. 131:0-0(2021).
CC   -!- FUNCTION: Tyrosine-protein kinase that plays an essential role as cell
CC       surface receptor for neuregulins. Binds to neuregulin-1 (NRG1) and is
CC       activated by it; ligand-binding increases phosphorylation on tyrosine
CC       residues and promotes its association with the p85 subunit of
CC       phosphatidylinositol 3-kinase (PubMed:20682778). May also be activated
CC       by CSPG5 (PubMed:15358134). Involved in the regulation of myeloid cell
CC       differentiation (PubMed:27416908). {ECO:0000269|PubMed:15358134,
CC       ECO:0000269|PubMed:20682778, ECO:0000269|PubMed:27416908}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.10.1;
CC         Evidence={ECO:0000269|PubMed:20351256};
CC   -!- SUBUNIT: Monomer and homodimer. Heterodimer with each of the other ERBB
CC       receptors (Potential). Interacts with CSPG5 (PubMed:15358134).
CC       Interacts with GRB7 (PubMed:9516479). Interacts with MUC1
CC       (PubMed:12939402). Interacts with MYOC (By similarity). Interacts with
CC       isoform 2 of PA2G4 (PubMed:11325528, PubMed:16832058). Found in a
CC       ternary complex with NRG1 and ITGAV:ITGB3 or ITGA6:ITGB4
CC       (PubMed:20682778). {ECO:0000250|UniProtKB:Q61526,
CC       ECO:0000269|PubMed:11325528, ECO:0000269|PubMed:12939402,
CC       ECO:0000269|PubMed:15358134, ECO:0000269|PubMed:16832058,
CC       ECO:0000269|PubMed:20682778, ECO:0000269|PubMed:9516479, ECO:0000305}.
CC   -!- INTERACTION:
CC       P21860; P42684: ABL2; NbExp=10; IntAct=EBI-720706, EBI-1102694;
CC       P21860; P46108: CRK; NbExp=2; IntAct=EBI-720706, EBI-886;
CC       P21860; P46109: CRKL; NbExp=3; IntAct=EBI-720706, EBI-910;
CC       P21860; P00533: EGFR; NbExp=13; IntAct=EBI-720706, EBI-297353;
CC       P21860; P04626: ERBB2; NbExp=29; IntAct=EBI-720706, EBI-641062;
CC       P21860; P21860: ERBB3; NbExp=2; IntAct=EBI-720706, EBI-720706;
CC       P21860; Q15303: ERBB4; NbExp=4; IntAct=EBI-720706, EBI-80371;
CC       P21860; P62993: GRB2; NbExp=3; IntAct=EBI-720706, EBI-401755;
CC       P21860; Q14451: GRB7; NbExp=7; IntAct=EBI-720706, EBI-970191;
CC       P21860; P25098: GRK2; NbExp=3; IntAct=EBI-720706, EBI-3904795;
CC       P21860; P08631: HCK; NbExp=2; IntAct=EBI-720706, EBI-346340;
CC       P21860; P08238: HSP90AB1; NbExp=3; IntAct=EBI-720706, EBI-352572;
CC       P21860; Q96JA1: LRIG1; NbExp=2; IntAct=EBI-720706, EBI-2865191;
CC       P21860; O43639: NCK2; NbExp=2; IntAct=EBI-720706, EBI-713635;
CC       P21860; Q02297-6: NRG1; NbExp=2; IntAct=EBI-720706, EBI-15651799;
CC       P21860; Q02297-7: NRG1; NbExp=3; IntAct=EBI-720706, EBI-2460927;
CC       P21860; P42336: PIK3CA; NbExp=3; IntAct=EBI-720706, EBI-2116585;
CC       P21860; P27986: PIK3R1; NbExp=41; IntAct=EBI-720706, EBI-79464;
CC       P21860; O00459: PIK3R2; NbExp=16; IntAct=EBI-720706, EBI-346930;
CC       P21860; Q92569: PIK3R3; NbExp=22; IntAct=EBI-720706, EBI-79893;
CC       P21860; P19174: PLCG1; NbExp=4; IntAct=EBI-720706, EBI-79387;
CC       P21860; P20936: RASA1; NbExp=6; IntAct=EBI-720706, EBI-1026476;
CC       P21860; Q13671: RIN1; NbExp=2; IntAct=EBI-720706, EBI-366017;
CC       P21860; P26447: S100A4; NbExp=4; IntAct=EBI-720706, EBI-717058;
CC       P21860; P04271: S100B; NbExp=3; IntAct=EBI-720706, EBI-458391;
CC       P21860; Q9UQQ2: SH2B3; NbExp=2; IntAct=EBI-720706, EBI-7879749;
CC       P21860; P29353: SHC1; NbExp=6; IntAct=EBI-720706, EBI-78835;
CC       P21860; Q92529: SHC3; NbExp=2; IntAct=EBI-720706, EBI-79084;
CC       P21860; P12931: SRC; NbExp=2; IntAct=EBI-720706, EBI-621482;
CC       P21860; P43405: SYK; NbExp=6; IntAct=EBI-720706, EBI-78302;
CC       P21860; Q63HR2: TNS2; NbExp=3; IntAct=EBI-720706, EBI-949753;
CC       P21860; Q68CZ2: TNS3; NbExp=2; IntAct=EBI-720706, EBI-1220488;
CC   -!- SUBCELLULAR LOCATION: [Isoform 1]: Cell membrane
CC       {ECO:0000269|PubMed:33497358}; Single-pass type I membrane protein.
CC   -!- SUBCELLULAR LOCATION: [Isoform 2]: Secreted.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=1; Synonyms=long form;
CC         IsoId=P21860-1; Sequence=Displayed;
CC       Name=2; Synonyms=short form;
CC         IsoId=P21860-2; Sequence=VSP_002893, VSP_002894;
CC       Name=3;
CC         IsoId=P21860-3; Sequence=VSP_041663, VSP_041664;
CC       Name=4;
CC         IsoId=P21860-4; Sequence=VSP_041662;
CC       Name=5;
CC         IsoId=P21860-5; Sequence=VSP_041661;
CC   -!- TISSUE SPECIFICITY: Epithelial tissues and brain.
CC   -!- DEVELOPMENTAL STAGE: Overexpressed in a subset of human mammary tumors.
CC   -!- DOMAIN: The cytoplasmic part of the receptor may interact with the SH2
CC       or SH3 domains of many signal-transducing proteins.
CC   -!- PTM: Autophosphorylated (PubMed:20351256). Ligand-binding increases
CC       phosphorylation on tyrosine residues and promotes its association with
CC       the p85 subunit of phosphatidylinositol 3-kinase (PubMed:20682778).
CC       {ECO:0000269|PubMed:20351256, ECO:0000269|PubMed:20682778,
CC       ECO:0000269|PubMed:33497358}.
CC   -!- DISEASE: Lethal congenital contracture syndrome 2 (LCCS2) [MIM:607598]:
CC       A form of lethal congenital contracture syndrome, an autosomal
CC       recessive disorder characterized by degeneration of anterior horn
CC       neurons, extreme skeletal muscle atrophy, and congenital non-
CC       progressive joint contractures (arthrogryposis). The contractures can
CC       involve the upper or lower limbs and/or the vertebral column, leading
CC       to various degrees of flexion or extension limitations evident at
CC       birth. LCCS2 patients manifest craniofacial/ocular findings, lack of
CC       hydrops, multiple pterygia, and fractures, as well as a normal duration
CC       of pregnancy and a unique feature of a markedly distended urinary
CC       bladder (neurogenic bladder defect). The phenotype suggests a spinal
CC       cord neuropathic etiology. {ECO:0000269|PubMed:17701904}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Erythroleukemia, familial (FERLK) [MIM:133180]: An autosomal
CC       dominant myeloproliferative disorder characterized by neoplastic
CC       proliferation of erythroblastic and myeloblastic elements with atypical
CC       erythroblasts and myeloblasts in the peripheral blood. Disease
CC       penetrance is incomplete. {ECO:0000269|PubMed:27416908}. Note=Disease
CC       susceptibility may be associated with variants affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Visceral neuropathy, familial, 1, autosomal recessive (VSCN1)
CC       [MIM:243180]: An autosomal recessive disorder characterized by
CC       intestinal dysmotility due to aganglionosis (Hirschsprung disease),
CC       hypoganglionosis, and/or chronic intestinal pseudoobstruction.
CC       Additional variable features are progressive peripheral neuropathy,
CC       arthrogryposis, hypoplasia or aplasia of the olfactory bulb and of the
CC       external auditory canals, microtia or anotia, and facial dysmorphism.
CC       Some patients present structural cardiac anomalies and arthrogryposis
CC       with multiple pterygia. {ECO:0000269|PubMed:33497358}. Note=The disease
CC       is caused by variants affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. EGF receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/ERBB3ID40479ch12q13.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M29366; AAA35790.1; -; mRNA.
DR   EMBL; M34309; AAA35979.1; -; mRNA.
DR   EMBL; S61953; AAB26935.1; -; mRNA.
DR   EMBL; BT007226; AAP35890.1; -; mRNA.
DR   EMBL; AK291681; BAF84370.1; -; mRNA.
DR   EMBL; AK295650; BAG58519.1; -; mRNA.
DR   EMBL; AK300909; BAG62544.1; -; mRNA.
DR   EMBL; AC034102; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC002706; AAH02706.1; -; mRNA.
DR   EMBL; BC082992; AAH82992.1; -; mRNA.
DR   CCDS; CCDS31833.1; -. [P21860-1]
DR   CCDS; CCDS44918.1; -. [P21860-2]
DR   PIR; A36223; A36223.
DR   PIR; JH0803; JH0803.
DR   RefSeq; NP_001005915.1; NM_001005915.1. [P21860-2]
DR   RefSeq; NP_001973.2; NM_001982.3. [P21860-1]
DR   PDB; 1M6B; X-ray; 2.60 A; A/B=20-640.
DR   PDB; 2L9U; NMR; -; A/B=639-670.
DR   PDB; 3KEX; X-ray; 2.80 A; A/B=698-1019.
DR   PDB; 3LMG; X-ray; 2.80 A; A/B=684-1020.
DR   PDB; 3P11; X-ray; 3.70 A; A=20-532.
DR   PDB; 4LEO; X-ray; 2.64 A; C=20-631.
DR   PDB; 4P59; X-ray; 3.40 A; A=20-640.
DR   PDB; 4RIW; X-ray; 3.10 A; A/C=698-1020.
DR   PDB; 4RIX; X-ray; 3.10 A; A/C=698-1020.
DR   PDB; 4RIY; X-ray; 2.98 A; A/C=698-1020.
DR   PDB; 5CUS; X-ray; 3.20 A; A/B/C/D=20-641.
DR   PDB; 5O4O; X-ray; 3.40 A; C=1-643.
DR   PDB; 5O7P; X-ray; 4.50 A; C=1-643.
DR   PDB; 6KBI; X-ray; 3.00 A; A/B=20-639.
DR   PDB; 6OP9; X-ray; 2.50 A; A=674-1001.
DR   PDB; 7BHE; X-ray; 2.30 A; B/D=500-643.
DR   PDB; 7BHF; X-ray; 2.00 A; B/D=500-630.
DR   PDB; 7D85; X-ray; 2.50 A; A/D=328-519.
DR   PDB; 7MN5; EM; 2.93 A; A=1-1021.
DR   PDB; 7MN6; EM; 3.09 A; A=1-1021.
DR   PDB; 7MN8; EM; 3.45 A; A=1-1021.
DR   PDBsum; 1M6B; -.
DR   PDBsum; 2L9U; -.
DR   PDBsum; 3KEX; -.
DR   PDBsum; 3LMG; -.
DR   PDBsum; 3P11; -.
DR   PDBsum; 4LEO; -.
DR   PDBsum; 4P59; -.
DR   PDBsum; 4RIW; -.
DR   PDBsum; 4RIX; -.
DR   PDBsum; 4RIY; -.
DR   PDBsum; 5CUS; -.
DR   PDBsum; 5O4O; -.
DR   PDBsum; 5O7P; -.
DR   PDBsum; 6KBI; -.
DR   PDBsum; 6OP9; -.
DR   PDBsum; 7BHE; -.
DR   PDBsum; 7BHF; -.
DR   PDBsum; 7D85; -.
DR   PDBsum; 7MN5; -.
DR   PDBsum; 7MN6; -.
DR   PDBsum; 7MN8; -.
DR   AlphaFoldDB; P21860; -.
DR   SMR; P21860; -.
DR   BioGRID; 108377; 295.
DR   CORUM; P21860; -.
DR   DIP; DIP-36441N; -.
DR   ELM; P21860; -.
DR   IntAct; P21860; 249.
DR   MINT; P21860; -.
DR   STRING; 9606.ENSP00000267101; -.
DR   BindingDB; P21860; -.
DR   ChEMBL; CHEMBL5838; -.
DR   DrugBank; DB11652; Tucatinib.
DR   DrugCentral; P21860; -.
DR   GuidetoPHARMACOLOGY; 1798; -.
DR   MoonDB; P21860; Predicted.
DR   TCDB; 8.A.23.1.39; the basigin (basigin) family.
DR   CarbonylDB; P21860; -.
DR   GlyConnect; 1711; 5 N-Linked glycans (3 sites).
DR   GlyGen; P21860; 10 sites, 5 N-linked glycans (3 sites).
DR   iPTMnet; P21860; -.
DR   PhosphoSitePlus; P21860; -.
DR   BioMuta; ERBB3; -.
DR   DMDM; 119534; -.
DR   EPD; P21860; -.
DR   jPOST; P21860; -.
DR   MassIVE; P21860; -.
DR   MaxQB; P21860; -.
DR   PaxDb; P21860; -.
DR   PeptideAtlas; P21860; -.
DR   PRIDE; P21860; -.
DR   ProteomicsDB; 53934; -. [P21860-1]
DR   ProteomicsDB; 53935; -. [P21860-2]
DR   ProteomicsDB; 53936; -. [P21860-3]
DR   ProteomicsDB; 53937; -. [P21860-4]
DR   ProteomicsDB; 53938; -. [P21860-5]
DR   ABCD; P21860; 104 sequenced antibodies.
DR   Antibodypedia; 3428; 2781 antibodies from 51 providers.
DR   CPTC; P21860; 3 antibodies.
DR   DNASU; 2065; -.
DR   Ensembl; ENST00000267101.8; ENSP00000267101.4; ENSG00000065361.17. [P21860-1]
DR   Ensembl; ENST00000411731.6; ENSP00000415753.2; ENSG00000065361.17. [P21860-2]
DR   Ensembl; ENST00000415288.6; ENSP00000408340.2; ENSG00000065361.17. [P21860-4]
DR   Ensembl; ENST00000551242.5; ENSP00000447510.1; ENSG00000065361.17. [P21860-3]
DR   Ensembl; ENST00000683018.1; ENSP00000506822.1; ENSG00000065361.17. [P21860-4]
DR   Ensembl; ENST00000683059.1; ENSP00000507402.1; ENSG00000065361.17. [P21860-4]
DR   Ensembl; ENST00000683164.1; ENSP00000508051.1; ENSG00000065361.17. [P21860-4]
DR   GeneID; 2065; -.
DR   KEGG; hsa:2065; -.
DR   MANE-Select; ENST00000267101.8; ENSP00000267101.4; NM_001982.4; NP_001973.2.
DR   UCSC; uc001sjg.4; human. [P21860-1]
DR   CTD; 2065; -.
DR   DisGeNET; 2065; -.
DR   GeneCards; ERBB3; -.
DR   HGNC; HGNC:3431; ERBB3.
DR   HPA; ENSG00000065361; Low tissue specificity.
DR   MalaCards; ERBB3; -.
DR   MIM; 133180; phenotype.
DR   MIM; 190151; gene.
DR   MIM; 243180; phenotype.
DR   MIM; 607598; phenotype.
DR   neXtProt; NX_P21860; -.
DR   OpenTargets; ENSG00000065361; -.
DR   Orphanet; 388; Hirschsprung disease.
DR   Orphanet; 137776; Lethal congenital contracture syndrome type 2.
DR   PharmGKB; PA27846; -.
DR   VEuPathDB; HostDB:ENSG00000065361; -.
DR   eggNOG; KOG1025; Eukaryota.
DR   GeneTree; ENSGT00940000156107; -.
DR   HOGENOM; CLU_003384_3_0_1; -.
DR   InParanoid; P21860; -.
DR   OMA; THEEVCP; -.
DR   OrthoDB; 81952at2759; -.
DR   PhylomeDB; P21860; -.
DR   TreeFam; TF106002; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   PathwayCommons; P21860; -.
DR   Reactome; R-HSA-1227986; Signaling by ERBB2. [P21860-1]
DR   Reactome; R-HSA-1236394; Signaling by ERBB4. [P21860-1]
DR   Reactome; R-HSA-1250196; SHC1 events in ERBB2 signaling. [P21860-1]
DR   Reactome; R-HSA-1257604; PIP3 activates AKT signaling. [P21860-1]
DR   Reactome; R-HSA-1306955; GRB7 events in ERBB2 signaling. [P21860-1]
DR   Reactome; R-HSA-1358803; Downregulation of ERBB2:ERBB3 signaling. [P21860-1]
DR   Reactome; R-HSA-1963642; PI3K events in ERBB2 signaling. [P21860-1]
DR   Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer. [P21860-1]
DR   Reactome; R-HSA-5673001; RAF/MAP kinase cascade. [P21860-1]
DR   Reactome; R-HSA-6785631; ERBB2 Regulates Cell Motility. [P21860-1]
DR   Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling. [P21860-1]
DR   Reactome; R-HSA-8847993; ERBB2 Activates PTK6 Signaling. [P21860-1]
DR   Reactome; R-HSA-8863795; Downregulation of ERBB2 signaling. [P21860-1]
DR   Reactome; R-HSA-9664565; Signaling by ERBB2 KD Mutants. [P21860-1]
DR   Reactome; R-HSA-9665686; Signaling by ERBB2 TMD/JMD mutants. [P21860-1]
DR   SignaLink; P21860; -.
DR   SIGNOR; P21860; -.
DR   BioGRID-ORCS; 2065; 83 hits in 1113 CRISPR screens.
DR   ChiTaRS; ERBB3; human.
DR   EvolutionaryTrace; P21860; -.
DR   GeneWiki; ERBB3; -.
DR   GenomeRNAi; 2065; -.
DR   Pharos; P21860; Tclin.
DR   PRO; PR:P21860; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   RNAct; P21860; protein.
DR   Bgee; ENSG00000065361; Expressed in trigeminal ganglion and 189 other tissues.
DR   ExpressionAtlas; P21860; baseline and differential.
DR   Genevisible; P21860; HS.
DR   GO; GO:0016324; C:apical plasma membrane; IEA:Ensembl.
DR   GO; GO:0009925; C:basal plasma membrane; IBA:GO_Central.
DR   GO; GO:0016323; C:basolateral plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0038143; C:ERBB3:ERBB2 complex; IDA:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; IDA:BHF-UCL.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:0016328; C:lateral plasma membrane; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; TAS:BHF-UCL.
DR   GO; GO:0043235; C:receptor complex; IDA:MGI.
DR   GO; GO:0044214; C:spanning component of plasma membrane; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0043125; F:ErbB-3 class receptor binding; IPI:UniProtKB.
DR   GO; GO:0019838; F:growth factor binding; IPI:BHF-UCL.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0038132; F:neuregulin binding; IDA:UniProtKB.
DR   GO; GO:0038131; F:neuregulin receptor activity; IBA:GO_Central.
DR   GO; GO:0046982; F:protein heterodimerization activity; IPI:BHF-UCL.
DR   GO; GO:0004672; F:protein kinase activity; IEA:InterPro.
DR   GO; GO:0030296; F:protein tyrosine kinase activator activity; IDA:BHF-UCL.
DR   GO; GO:0004888; F:transmembrane signaling receptor activity; ISS:BHF-UCL.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:CAFA.
DR   GO; GO:0021545; P:cranial nerve development; ISS:BHF-UCL.
DR   GO; GO:0003197; P:endocardial cushion development; IEA:Ensembl.
DR   GO; GO:0038133; P:ERBB2-ERBB3 signaling pathway; IEA:Ensembl.
DR   GO; GO:0097192; P:extrinsic apoptotic signaling pathway in absence of ligand; IMP:BHF-UCL.
DR   GO; GO:0007507; P:heart development; ISS:BHF-UCL.
DR   GO; GO:0097049; P:motor neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0007162; P:negative regulation of cell adhesion; IDA:BHF-UCL.
DR   GO; GO:2000672; P:negative regulation of motor neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; ISS:BHF-UCL.
DR   GO; GO:0051048; P:negative regulation of secretion; IDA:BHF-UCL.
DR   GO; GO:0009968; P:negative regulation of signal transduction; IDA:BHF-UCL.
DR   GO; GO:0007399; P:nervous system development; IBA:GO_Central.
DR   GO; GO:0051402; P:neuron apoptotic process; IMP:BHF-UCL.
DR   GO; GO:0007422; P:peripheral nervous system development; ISS:BHF-UCL.
DR   GO; GO:0014065; P:phosphatidylinositol 3-kinase signaling; IDA:BHF-UCL.
DR   GO; GO:0070886; P:positive regulation of calcineurin-NFAT signaling cascade; IEA:Ensembl.
DR   GO; GO:0055025; P:positive regulation of cardiac muscle tissue development; IEA:Ensembl.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IBA:GO_Central.
DR   GO; GO:0010628; P:positive regulation of gene expression; IEA:Ensembl.
DR   GO; GO:0033674; P:positive regulation of kinase activity; IBA:GO_Central.
DR   GO; GO:0014068; P:positive regulation of phosphatidylinositol 3-kinase signaling; TAS:BHF-UCL.
DR   GO; GO:0061098; P:positive regulation of protein tyrosine kinase activity; IMP:BHF-UCL.
DR   GO; GO:0006468; P:protein phosphorylation; IEA:InterPro.
DR   GO; GO:0042127; P:regulation of cell population proliferation; IDA:BHF-UCL.
DR   GO; GO:0014037; P:Schwann cell differentiation; ISS:BHF-UCL.
DR   GO; GO:0007165; P:signal transduction; IDA:UniProtKB.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; ISS:BHF-UCL.
DR   GO; GO:0042060; P:wound healing; NAS:BHF-UCL.
DR   CDD; cd00064; FU; 3.
DR   Gene3D; 3.80.20.20; -; 2.
DR   InterPro; IPR006211; Furin-like_Cys-rich_dom.
DR   InterPro; IPR006212; Furin_repeat.
DR   InterPro; IPR032778; GF_recep_IV.
DR   InterPro; IPR009030; Growth_fac_rcpt_cys_sf.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR000494; Rcpt_L-dom.
DR   InterPro; IPR036941; Rcpt_L-dom_sf.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR016245; Tyr_kinase_EGF/ERB/XmrK_rcpt.
DR   Pfam; PF00757; Furin-like; 1.
DR   Pfam; PF14843; GF_recep_IV; 1.
DR   Pfam; PF07714; PK_Tyr_Ser-Thr; 1.
DR   Pfam; PF01030; Recep_L_domain; 2.
DR   PIRSF; PIRSF000619; TyrPK_EGF-R; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00261; FU; 5.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF57184; SSF57184; 2.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell membrane;
KW   Disease variant; Disulfide bond; Glycoprotein; Kinase; Membrane;
KW   Nucleotide-binding; Phosphoprotein; Receptor; Reference proteome; Secreted;
KW   Signal; Transferase; Transmembrane; Transmembrane helix;
KW   Tyrosine-protein kinase.
FT   SIGNAL          1..19
FT                   /evidence="ECO:0000255"
FT   CHAIN           20..1342
FT                   /note="Receptor tyrosine-protein kinase erbB-3"
FT                   /id="PRO_0000016672"
FT   TOPO_DOM        20..643
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        644..664
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        665..1342
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          709..966
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          980..999
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1033..1152
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1033..1076
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1111..1132
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        834
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         715..723
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT   BINDING         742
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT   BINDING         788..790
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT   BINDING         834..839
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT   MOD_RES         686
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         982
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   CARBOHYD        126
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        250
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:12154198"
FT   CARBOHYD        353
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:12154198"
FT   CARBOHYD        408
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:12154198"
FT   CARBOHYD        414
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:12154198"
FT   CARBOHYD        437
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:12154198"
FT   CARBOHYD        469
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:12154198"
FT   CARBOHYD        522
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:12154198"
FT   CARBOHYD        566
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:12154198"
FT   CARBOHYD        616
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        29..56
FT                   /evidence="ECO:0000269|PubMed:12154198"
FT   DISULFID        156..183
FT                   /evidence="ECO:0000269|PubMed:12154198"
FT   DISULFID        186..194
FT                   /evidence="ECO:0000269|PubMed:12154198"
FT   DISULFID        190..202
FT                   /evidence="ECO:0000269|PubMed:12154198"
FT   DISULFID        210..218
FT                   /evidence="ECO:0000269|PubMed:12154198"
FT   DISULFID        214..226
FT                   /evidence="ECO:0000269|PubMed:12154198"
FT   DISULFID        227..235
FT                   /evidence="ECO:0000269|PubMed:12154198"
FT   DISULFID        231..243
FT                   /evidence="ECO:0000269|PubMed:12154198"
FT   DISULFID        246..255
FT                   /evidence="ECO:0000269|PubMed:12154198"
FT   DISULFID        259..286
FT                   /evidence="ECO:0000269|PubMed:12154198"
FT   DISULFID        290..301
FT                   /evidence="ECO:0000269|PubMed:12154198"
FT   DISULFID        305..320
FT                   /evidence="ECO:0000269|PubMed:12154198"
FT   DISULFID        323..327
FT                   /evidence="ECO:0000269|PubMed:12154198"
FT   DISULFID        500..509
FT                   /evidence="ECO:0000269|PubMed:12154198"
FT   DISULFID        504..517
FT                   /evidence="ECO:0000269|PubMed:12154198"
FT   DISULFID        520..529
FT                   /evidence="ECO:0000269|PubMed:12154198"
FT   DISULFID        533..549
FT                   /evidence="ECO:0000269|PubMed:12154198"
FT   DISULFID        552..565
FT                   /evidence="ECO:0000269|PubMed:12154198"
FT   DISULFID        556..573
FT                   /evidence="ECO:0000269|PubMed:12154198"
FT   DISULFID        576..585
FT                   /evidence="ECO:0000269|PubMed:12154198"
FT   DISULFID        589..610
FT                   /evidence="ECO:0000250"
FT   DISULFID        613..621
FT                   /evidence="ECO:0000250"
FT   DISULFID        617..629
FT                   /evidence="ECO:0000250"
FT   VAR_SEQ         1..643
FT                   /note="Missing (in isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_041661"
FT   VAR_SEQ         1..59
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_041662"
FT   VAR_SEQ         141..183
FT                   /note="EILSGGVYIEKNDKLCHMDTIDWRDIVRDRDAEIVVKDNGRSC -> GQFPM
FT                   VPSGLTPQPAQDWYLLDDDPRLLTLSASSKVPVTLAAV (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:7685162"
FT                   /id="VSP_002893"
FT   VAR_SEQ         184..1342
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:7685162"
FT                   /id="VSP_002894"
FT   VAR_SEQ         331
FT                   /note="C -> F (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334, ECO:0000303|Ref.4"
FT                   /id="VSP_041663"
FT   VAR_SEQ         332..1342
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334, ECO:0000303|Ref.4"
FT                   /id="VSP_041664"
FT   VARIANT         20
FT                   /note="S -> Y (in dbSNP:rs34379766)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042101"
FT   VARIANT         30
FT                   /note="P -> L (in dbSNP:rs56017157)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042102"
FT   VARIANT         104
FT                   /note="V -> M (in an ovarian mucinous carcinoma sample;
FT                   somatic mutation; dbSNP:rs1057519893)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042103"
FT   VARIANT         204
FT                   /note="T -> I (in dbSNP:rs56107455)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042104"
FT   VARIANT         385
FT                   /note="N -> S (in dbSNP:rs12320176)"
FT                   /id="VAR_049710"
FT   VARIANT         683
FT                   /note="R -> W (in dbSNP:rs56387488)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042105"
FT   VARIANT         717
FT                   /note="S -> L (in dbSNP:rs35961836)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042106"
FT   VARIANT         744
FT                   /note="I -> T (in dbSNP:rs55787439)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042107"
FT   VARIANT         787
FT                   /note="T -> P (in VSCN1; almost complete loss of ERBB2 and
FT                   ERBB3 phosphorylation in the presence or in the absence of
FT                   NRG1 stimulation, suggesting alteration of downstream
FT                   signaling; does not affect the subcellular localization at
FT                   the cell membrane)"
FT                   /evidence="ECO:0000269|PubMed:33497358"
FT                   /id="VAR_086108"
FT   VARIANT         873
FT                   /note="T -> S (in VSCN1; unknown pathological significance;
FT                   some decrease in ERBB2 phosphorylation upon NG1 treatment,
FT                   compared to wild-type; does not affect the subcellular
FT                   localization at the cell membrane)"
FT                   /evidence="ECO:0000269|PubMed:33497358"
FT                   /id="VAR_086109"
FT   VARIANT         899
FT                   /note="V -> M (in VSCN1; almost complete loss of ERBB2 and
FT                   ERBB3 phosphorylation in the presence or in the absence of
FT                   NRG1 stimulation, suggesting alteration of downstream
FT                   signaling; does not affect the subcellular localization at
FT                   the cell membrane)"
FT                   /evidence="ECO:0000269|PubMed:33497358"
FT                   /id="VAR_086110"
FT   VARIANT         932
FT                   /note="Q -> R (in VSCN1; unknown pathological significance;
FT                   some decrease in ERBB2 phosphorylation upon NG1 treatment,
FT                   compared to wild-type; does not affect the subcellular
FT                   localization at the cell membrane)"
FT                   /evidence="ECO:0000269|PubMed:33497358"
FT                   /id="VAR_086111"
FT   VARIANT         998
FT                   /note="K -> R (in dbSNP:rs56259600)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042108"
FT   VARIANT         1119
FT                   /note="S -> C (in dbSNP:rs773123)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042109"
FT   VARIANT         1127
FT                   /note="R -> H (in dbSNP:rs2271188)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042110"
FT   VARIANT         1177
FT                   /note="L -> I (in dbSNP:rs55699040)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042111"
FT   VARIANT         1254
FT                   /note="T -> K (in dbSNP:rs55709407)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042112"
FT   VARIANT         1271
FT                   /note="G -> S (in dbSNP:rs11171743)"
FT                   /id="VAR_049711"
FT   VARIANT         1337
FT                   /note="A -> T (in FERLK; risk factor for erythroleukemia;
FT                   results in increased ERBB-mediated signaling; results in a
FT                   block of erythroid differentiation and increased cell
FT                   proliferation; dbSNP:rs755855285)"
FT                   /evidence="ECO:0000269|PubMed:27416908"
FT                   /id="VAR_081641"
FT   MUTAGEN         742
FT                   /note="K->M: Strongly reduced autophosphorylation."
FT                   /evidence="ECO:0000269|PubMed:20351256"
FT   MUTAGEN         868
FT                   /note="Y->E: Strongly reduced tyrosine phosphorylation."
FT                   /evidence="ECO:0000269|PubMed:20351256"
FT   CONFLICT        560
FT                   /note="E -> G (in Ref. 2; AAA35979)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        684
FT                   /note="G -> S (in Ref. 5; BAF84370)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1064
FT                   /note="E -> G (in Ref. 2; AAA35979)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1078
FT                   /note="C -> S (in Ref. 5; BAG62544)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1163
FT                   /note="D -> G (in Ref. 5; BAF84370)"
FT                   /evidence="ECO:0000305"
FT   STRAND          28..30
FT                   /evidence="ECO:0007829|PDB:4LEO"
FT   STRAND          38..41
FT                   /evidence="ECO:0007829|PDB:7MN5"
FT   HELIX           43..53
FT                   /evidence="ECO:0007829|PDB:4LEO"
FT   STRAND          58..61
FT                   /evidence="ECO:0007829|PDB:1M6B"
FT   STRAND          63..67
FT                   /evidence="ECO:0007829|PDB:1M6B"
FT   HELIX           75..79
FT                   /evidence="ECO:0007829|PDB:1M6B"
FT   STRAND          82..85
FT                   /evidence="ECO:0007829|PDB:1M6B"
FT   STRAND          87..91
FT                   /evidence="ECO:0007829|PDB:1M6B"
FT   STRAND          95..98
FT                   /evidence="ECO:0007829|PDB:1M6B"
FT   TURN            112..114
FT                   /evidence="ECO:0007829|PDB:1M6B"
FT   STRAND          115..120
FT                   /evidence="ECO:0007829|PDB:1M6B"
FT   STRAND          125..128
FT                   /evidence="ECO:0007829|PDB:4LEO"
FT   STRAND          133..135
FT                   /evidence="ECO:0007829|PDB:1M6B"
FT   STRAND          141..144
FT                   /evidence="ECO:0007829|PDB:7MN6"
FT   STRAND          146..150
FT                   /evidence="ECO:0007829|PDB:1M6B"
FT   TURN            158..160
FT                   /evidence="ECO:0007829|PDB:1M6B"
FT   HELIX           163..166
FT                   /evidence="ECO:0007829|PDB:1M6B"
FT   STRAND          174..178
FT                   /evidence="ECO:0007829|PDB:1M6B"
FT   HELIX           188..190
FT                   /evidence="ECO:0007829|PDB:4LEO"
FT   STRAND          194..198
FT                   /evidence="ECO:0007829|PDB:1M6B"
FT   HELIX           199..201
FT                   /evidence="ECO:0007829|PDB:7MN5"
FT   STRAND          214..216
FT                   /evidence="ECO:0007829|PDB:1M6B"
FT   STRAND          218..222
FT                   /evidence="ECO:0007829|PDB:1M6B"
FT   HELIX           223..225
FT                   /evidence="ECO:0007829|PDB:5CUS"
FT   STRAND          231..233
FT                   /evidence="ECO:0007829|PDB:1M6B"
FT   STRAND          235..239
FT                   /evidence="ECO:0007829|PDB:1M6B"
FT   HELIX           240..242
FT                   /evidence="ECO:0007829|PDB:1M6B"
FT   STRAND          243..251
FT                   /evidence="ECO:0007829|PDB:1M6B"
FT   STRAND          254..258
FT                   /evidence="ECO:0007829|PDB:1M6B"
FT   STRAND          262..265
FT                   /evidence="ECO:0007829|PDB:1M6B"
FT   TURN            267..269
FT                   /evidence="ECO:0007829|PDB:1M6B"
FT   STRAND          270..274
FT                   /evidence="ECO:0007829|PDB:1M6B"
FT   STRAND          280..282
FT                   /evidence="ECO:0007829|PDB:1M6B"
FT   STRAND          285..289
FT                   /evidence="ECO:0007829|PDB:1M6B"
FT   STRAND          295..297
FT                   /evidence="ECO:0007829|PDB:1M6B"
FT   STRAND          300..304
FT                   /evidence="ECO:0007829|PDB:1M6B"
FT   STRAND          309..314
FT                   /evidence="ECO:0007829|PDB:1M6B"
FT   STRAND          317..322
FT                   /evidence="ECO:0007829|PDB:1M6B"
FT   STRAND          324..326
FT                   /evidence="ECO:0007829|PDB:4LEO"
FT   STRAND          330..332
FT                   /evidence="ECO:0007829|PDB:7D85"
FT   STRAND          338..342
FT                   /evidence="ECO:0007829|PDB:5CUS"
FT   TURN            345..347
FT                   /evidence="ECO:0007829|PDB:7D85"
FT   HELIX           348..351
FT                   /evidence="ECO:0007829|PDB:7D85"
FT   STRAND          355..363
FT                   /evidence="ECO:0007829|PDB:7D85"
FT   HELIX           365..369
FT                   /evidence="ECO:0007829|PDB:7D85"
FT   TURN            372..375
FT                   /evidence="ECO:0007829|PDB:7D85"
FT   HELIX           381..389
FT                   /evidence="ECO:0007829|PDB:7D85"
FT   STRAND          392..395
FT                   /evidence="ECO:0007829|PDB:7D85"
FT   STRAND          397..399
FT                   /evidence="ECO:0007829|PDB:7D85"
FT   HELIX           410..412
FT                   /evidence="ECO:0007829|PDB:7D85"
FT   TURN            425..427
FT                   /evidence="ECO:0007829|PDB:7D85"
FT   STRAND          428..433
FT                   /evidence="ECO:0007829|PDB:7D85"
FT   STRAND          451..457
FT                   /evidence="ECO:0007829|PDB:7D85"
FT   HELIX           465..467
FT                   /evidence="ECO:0007829|PDB:4LEO"
FT   HELIX           470..474
FT                   /evidence="ECO:0007829|PDB:7D85"
FT   STRAND          481..488
FT                   /evidence="ECO:0007829|PDB:7D85"
FT   HELIX           490..495
FT                   /evidence="ECO:0007829|PDB:7D85"
FT   STRAND          509..513
FT                   /evidence="ECO:0007829|PDB:7BHF"
FT   HELIX           514..516
FT                   /evidence="ECO:0007829|PDB:7BHF"
FT   STRAND          517..522
FT                   /evidence="ECO:0007829|PDB:7BHF"
FT   STRAND          528..531
FT                   /evidence="ECO:0007829|PDB:7BHE"
FT   STRAND          534..540
FT                   /evidence="ECO:0007829|PDB:7BHF"
FT   STRAND          542..545
FT                   /evidence="ECO:0007829|PDB:7BHF"
FT   STRAND          548..551
FT                   /evidence="ECO:0007829|PDB:7BHF"
FT   STRAND          560..562
FT                   /evidence="ECO:0007829|PDB:7BHF"
FT   STRAND          564..569
FT                   /evidence="ECO:0007829|PDB:7BHF"
FT   STRAND          572..581
FT                   /evidence="ECO:0007829|PDB:7BHF"
FT   STRAND          584..588
FT                   /evidence="ECO:0007829|PDB:7BHF"
FT   STRAND          591..595
FT                   /evidence="ECO:0007829|PDB:7BHF"
FT   STRAND          598..604
FT                   /evidence="ECO:0007829|PDB:7BHF"
FT   STRAND          608..612
FT                   /evidence="ECO:0007829|PDB:7BHF"
FT   STRAND          621..625
FT                   /evidence="ECO:0007829|PDB:7BHF"
FT   HELIX           626..628
FT                   /evidence="ECO:0007829|PDB:7BHF"
FT   HELIX           641..670
FT                   /evidence="ECO:0007829|PDB:2L9U"
FT   HELIX           706..708
FT                   /evidence="ECO:0007829|PDB:6OP9"
FT   STRAND          709..717
FT                   /evidence="ECO:0007829|PDB:6OP9"
FT   STRAND          722..728
FT                   /evidence="ECO:0007829|PDB:6OP9"
FT   STRAND          731..733
FT                   /evidence="ECO:0007829|PDB:3LMG"
FT   STRAND          737..744
FT                   /evidence="ECO:0007829|PDB:6OP9"
FT   TURN            747..749
FT                   /evidence="ECO:0007829|PDB:6OP9"
FT   STRAND          753..755
FT                   /evidence="ECO:0007829|PDB:4RIY"
FT   HELIX           758..764
FT                   /evidence="ECO:0007829|PDB:6OP9"
FT   STRAND          774..778
FT                   /evidence="ECO:0007829|PDB:6OP9"
FT   STRAND          780..788
FT                   /evidence="ECO:0007829|PDB:6OP9"
FT   HELIX           795..802
FT                   /evidence="ECO:0007829|PDB:6OP9"
FT   HELIX           803..806
FT                   /evidence="ECO:0007829|PDB:6OP9"
FT   HELIX           808..827
FT                   /evidence="ECO:0007829|PDB:6OP9"
FT   HELIX           837..839
FT                   /evidence="ECO:0007829|PDB:6OP9"
FT   STRAND          840..846
FT                   /evidence="ECO:0007829|PDB:6OP9"
FT   STRAND          848..850
FT                   /evidence="ECO:0007829|PDB:6OP9"
FT   HELIX           856..858
FT                   /evidence="ECO:0007829|PDB:6OP9"
FT   HELIX           865..868
FT                   /evidence="ECO:0007829|PDB:4RIY"
FT   TURN            870..872
FT                   /evidence="ECO:0007829|PDB:4RIY"
FT   HELIX           875..877
FT                   /evidence="ECO:0007829|PDB:6OP9"
FT   HELIX           880..885
FT                   /evidence="ECO:0007829|PDB:6OP9"
FT   HELIX           890..905
FT                   /evidence="ECO:0007829|PDB:6OP9"
FT   TURN            911..914
FT                   /evidence="ECO:0007829|PDB:6OP9"
FT   HELIX           917..919
FT                   /evidence="ECO:0007829|PDB:6OP9"
FT   HELIX           920..925
FT                   /evidence="ECO:0007829|PDB:6OP9"
FT   HELIX           938..947
FT                   /evidence="ECO:0007829|PDB:6OP9"
FT   TURN            952..954
FT                   /evidence="ECO:0007829|PDB:6OP9"
FT   HELIX           958..969
FT                   /evidence="ECO:0007829|PDB:6OP9"
FT   HELIX           972..974
FT                   /evidence="ECO:0007829|PDB:6OP9"
FT   STRAND          980..983
FT                   /evidence="ECO:0007829|PDB:3KEX"
SQ   SEQUENCE   1342 AA;  148098 MW;  7201E7F66CA374BD CRC64;
     MRANDALQVL GLLFSLARGS EVGNSQAVCP GTLNGLSVTG DAENQYQTLY KLYERCEVVM
     GNLEIVLTGH NADLSFLQWI REVTGYVLVA MNEFSTLPLP NLRVVRGTQV YDGKFAIFVM
     LNYNTNSSHA LRQLRLTQLT EILSGGVYIE KNDKLCHMDT IDWRDIVRDR DAEIVVKDNG
     RSCPPCHEVC KGRCWGPGSE DCQTLTKTIC APQCNGHCFG PNPNQCCHDE CAGGCSGPQD
     TDCFACRHFN DSGACVPRCP QPLVYNKLTF QLEPNPHTKY QYGGVCVASC PHNFVVDQTS
     CVRACPPDKM EVDKNGLKMC EPCGGLCPKA CEGTGSGSRF QTVDSSNIDG FVNCTKILGN
     LDFLITGLNG DPWHKIPALD PEKLNVFRTV REITGYLNIQ SWPPHMHNFS VFSNLTTIGG
     RSLYNRGFSL LIMKNLNVTS LGFRSLKEIS AGRIYISANR QLCYHHSLNW TKVLRGPTEE
     RLDIKHNRPR RDCVAEGKVC DPLCSSGGCW GPGPGQCLSC RNYSRGGVCV THCNFLNGEP
     REFAHEAECF SCHPECQPME GTATCNGSGS DTCAQCAHFR DGPHCVSSCP HGVLGAKGPI
     YKYPDVQNEC RPCHENCTQG CKGPELQDCL GQTLVLIGKT HLTMALTVIA GLVVIFMMLG
     GTFLYWRGRR IQNKRAMRRY LERGESIEPL DPSEKANKVL ARIFKETELR KLKVLGSGVF
     GTVHKGVWIP EGESIKIPVC IKVIEDKSGR QSFQAVTDHM LAIGSLDHAH IVRLLGLCPG
     SSLQLVTQYL PLGSLLDHVR QHRGALGPQL LLNWGVQIAK GMYYLEEHGM VHRNLAARNV
     LLKSPSQVQV ADFGVADLLP PDDKQLLYSE AKTPIKWMAL ESIHFGKYTH QSDVWSYGVT
     VWELMTFGAE PYAGLRLAEV PDLLEKGERL AQPQICTIDV YMVMVKCWMI DENIRPTFKE
     LANEFTRMAR DPPRYLVIKR ESGPGIAPGP EPHGLTNKKL EEVELEPELD LDLDLEAEED
     NLATTTLGSA LSLPVGTLNR PRGSQSLLSP SSGYMPMNQG NLGESCQESA VSGSSERCPR
     PVSLHPMPRG CLASESSEGH VTGSEAELQE KVSMCRSRSR SRSPRPRGDS AYHSQRHSLL
     TPVTPLSPPG LEEEDVNGYV MPDTHLKGTP SSREGTLSSV GLSSVLGTEE EDEDEEYEYM
     NRRRRHSPPH PPRPSSLEEL GYEYMDVGSD LSASLGSTQS CPLHPVPIMP TAGTTPDEDY
     EYMNRQRDGG GPGGDYAAMG ACPASEQGYE EMRAFQGPGH QAPHVHYARL KTLRSLEATD
     SAFDNPDYWH SRLFPKANAQ RT
//
